Xenon Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Xenon Pharmaceuticals Inc. announced its financial results for the three and six months ended June 30, 2026 via a press release; the company filed an 8-K on August 6, 2026 attaching that press release as Exhibit 99.1.
• The 8-K states the press release is furnished (not filed) with the SEC and confirms the company’s channels for disclosing material information, including its website and social media.

Key Details

• Press release covering Q2 2026 results attached as Exhibit 99.1 to the 8-K (filed August 6, 2026).
• Results reported are for the three- and six-month periods ended June 30, 2026.
• Company lists primary disclosure channels: SEC filings, press releases, investor website (https://investor.xenon-pharma.com), news site, X (@XenonPharma) and LinkedIn.
• 8-K signed by Thomas P. Kelly, Chief Financial Officer.

Why It Matters

• This filing notifies investors that Xenon has released its quarterly financial results; those results may contain revenue, expense, cash position and operational updates important to valuation and trading.
• The 8-K also reminds investors where the company posts material information (SEC filings, investor site, social media), so investors should review the attached press release and the company’s investor pages for the specific financial figures and management commentary.